Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Mayo Clinic
- 入组人数
- 635
- 试验地点
- 2
- 主要终点
- Future Disease Management
研究概览
简要总结
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
详细描述
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
- •Patients willing to provide written informed consent
排除标准
- •Unwillingness/unable to give blood samples
研究组 & 干预措施
Healthy
100 healthy participants as a control group.
干预措施: Healthy (Other)
ILD
250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
干预措施: ILD (Other)
Pneumonia
25 patients with pneumonia as a control group.
干预措施: Pneumonia (Other)
结局指标
主要结局
Future Disease Management
时间窗: 1 visit
Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.
次要结局
未报告次要终点
研究者
Eva M. Carmona Porquera
Assistant Professor of Medicine, College of Medicine
Mayo Clinic